Enliven therapeutics announces positive data update from phase 1 clinical trial of elvn-001 in chronic myeloid leukemia

Updated phase 1 data presented at esh-icmlf 26 th annual john goldman conference reported cumulative mmr rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent phase 1 trials of approved bcr::abl1 tkis elvn-001 remains well-tolerated with no dose reductions reported with 39 patients enrolled and a median treatment duration of 20 weeks at cutoff boulder, colo., sept. 28, 2024 (globe newswire) -- enliven therapeutics, inc. (enliven or the company) (nasdaq: elvn), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced updated, positive data from the phase 1 clinical trial evaluating elvn-001 in patients with chronic myeloid leukemia (cml) that has failed, or the patient is intolerant to or not a candidate for, available therapies known to be active for treatment of their cml (nct05304377) at the european society of hematology international chronic myeloid leukemia foundation (esh-icmlf) 26th annual john goldman conference.
ELVN Ratings Summary
ELVN Quant Ranking